Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
678 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01946204 | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer(SPARTAN) | active not recruiting | Phase 3 | 1,207 | Aragon Pharmaceuticals, Inc.INDUSTRY | 25 | Sep 28, 2026 | clinicaltrials |
| NCT03462719 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(GLOW) | active not recruiting | Phase 3 | 211 | Janssen Research & Development, LLC |
| 14 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma(CARTITUDE-4) | active not recruiting | Phase 3 | 419 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)(AMPLITUDE) | active not recruiting | Phase 3 | 696 | Janssen Research & Development, LLCINDUSTRY | 33 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT04988295 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2) | active not recruiting | Phase 3 | 776 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | recruiting | Phase 3 | 800 | PfizerINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT04472429 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | completed | Phase 3 | 308 | Incyte CorporationINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer(PRIMORDIUM) | active not recruiting | Phase 3 | 691 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy(CARTITUDE-5) | active not recruiting | Phase 3 | 743 | Janssen Research & Development, LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05083169 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-3) | active not recruiting | Phase 3 | 587 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | recruiting | Phase 2 / Phase 3 | 290 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05438043 | A Study of Daratumumab | active not recruiting | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 17 | Sep 25, 2026 | clinicaltrials |
| NCT05552222 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma(MajesTEC-7) | recruiting | Phase 3 | 1,590 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)(TroFuse-007) | recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide(MonumenTAL-6) | active not recruiting | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06319820 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer(MoonRISe-1) | recruiting | Phase 3 | 641 | Janssen Research & Development, LLCINDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | recruiting | Phase 3 | 1,530 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 25, 2026 | clinicaltrials |
| NCT06510374 | Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer(ABLE-32) | recruiting | Phase 3 | 454 | Ferring PharmaceuticalsINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer(ABLE-22) | recruiting | Phase 3 | 250 | Ferring PharmaceuticalsINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | recruiting | Phase 3 | 900 | PfizerINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | recruiting | Phase 3 | 1,000 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 25, 2026 | clinicaltrials |
| NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)(cAMeLot-2) | recruiting | Phase 3 | 600 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | recruiting | Phase 3 | 758 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 25, 2026 | clinicaltrials |
| NCT07570173 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | recruiting | Phase 2 / Phase 3 | 340 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05552976 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)(SUCCESSOR-2) | active not recruiting | Phase 3 | 606 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 24, 2026 | clinicaltrials |
| NCT06136559 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | recruiting | Phase 3 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 24, 2026 | clinicaltrials |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)(BRUIN-MCL-321) | active not recruiting | Phase 3 | 500 | Loxo Oncology, Inc.INDUSTRY | 24 | Sep 23, 2026 | clinicaltrials |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%(RELATIVITY1093) | recruiting | Phase 3 | 1,000 | Bristol-Myers SquibbINDUSTRY | 31 | Sep 23, 2026 | clinicaltrials |
| NCT07063745 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion(MountainTAP-29) | recruiting | Phase 2 / Phase 3 | 590 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 23, 2026 | clinicaltrials |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 23, 2026 | clinicaltrials |
| NCT06440967 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | active not recruiting | Phase 3 | 982 | Astellas Pharma Global Development, Inc.INDUSTRY | 11 | Sep 22, 2026 | clinicaltrials |
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer(FRAmework-01) | recruiting | Phase 3 | 1,630 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 22, 2026 | clinicaltrials |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract(FORAGER-2) | recruiting | Phase 3 | 450 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma(DAWN-303) | recruiting | Phase 3 | 588 | Incyte CorporationINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT05153239 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | completed | Phase 3 | 705 | PharmaMarINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT06549595 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT03435796 | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | recruiting | Phase 2 / Phase 3 | 1,541 | CelgeneINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | active not recruiting | Phase 3 | 990 | Merck Sharp & Dohme LLCINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT05038735 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.(EPIK-B5) | active not recruiting | Phase 3 | 210 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 18, 2026 | clinicaltrials |
Data updated 23 hours agoSource updated unknownsource: clinicaltrials